Engineered anti-IL-23 antibodies
US7807160B2 · kind B2 · utility
50Cited by
2References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 29, 2006 |
| Grant date | Oct 5, 2010 |
| Priority date | — |
| Expiry date | Aug 29, 2026 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Engineered antibodies to human IL-23p19 are provided, as well as uses thereof, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.